ACY-7 Oral Administration of Acyline

Completed · Phase 1/Phase 2

Conditions studied: Healthy

In brief

We propose oral dosing of gastrointestinal permeation enhancement technology \[GIPET\] enhanced oral acyline at 20 mg everyday for one week to determine the steady-state (multiple-dose) pharmacokinetics of oral acyline in four normal, healthy young men.

Key facts

Study ID

NCT00603187

Run by

University of Washington

People needed

4

Starts

2008-01-01

Expected to finish

2008-02-01

Last updated by the study team

2011-06-09

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy male
• 18-50 years of age
• Non-smoker
• Not taking any medications other than the study drug for the duration of the study.
• Must be willing to use an accepted method of contraception during the study.

You may not qualify if…

• BMI > 35
• Abnormal evaluation on screening exam and labs
• Known history of alcohol abuse, illicit drugs or steroids and/or use of more that 3 alcoholic beverages/day
• History of current testosterone use or infertility
• History of testicular disease or severe testicular trauma
• History of major psychiatric disorder or sleep apnea
• History of bleeding disorder or need for anticoagulation
• Current smoker or utilizing nicotine patches or gum
• Participation in a hormonal drug study within past month.

Where it is running

• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.